Title : The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity.

Pub. Date : 2010 Nov 1

PMID : 20143399






3 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 The BCR/ABL-inhibitors imatinib, nilotinib and dasatinib differentially affect NK cell reactivity. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
2 In chronic myeloid leukemia (CML), BCR/ABL-mediated oncogenic signaling can be targeted with the BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens
3 In chronic myeloid leukemia (CML), BCR/ABL-mediated oncogenic signaling can be targeted with the BCR/ABL-inhibitors Imatinib, Nilotinib and Dasatinib. nilotinib ABL proto-oncogene 1, non-receptor tyrosine kinase Homo sapiens